AGTC Announces Key Appointments to Leadership Team
June 08 2022 - 8:00AM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical
stage biotechnology company focused on the development of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare and debilitating diseases with an initial focus on
inherited retinal diseases, today announced the appointments of
Eduardo Jacobo, P.E., as Senior Vice President of GMP
Manufacturing, and Dr. David Jacobs, MD, MBA, FACP, as Senior Vice
President of Clinical Research and Medical Affairs.
Eduardo Jacobo has over 30 years of experience in the healthcare
industry, spending much of his time leading manufacturing, supply
chain, quality, engineering, and process development functions.
Eduardo comes to AGTC from Sangamo Therapeutics, where he led good
manufacturing practice (GMP) gene therapy manufacturing efforts,
including new facility commissioning. Prior to this, he held
positions of increasing responsibility across many manufacturing
programs at several companies, including Amgen, Eli Lilly and
Zimmer.
Dr. David Jacobs is a highly regarded clinician and
pharmaceutical executive who brings over 20 years of experience
spanning all aspects of biopharmaceutical product development.
Prior to joining AGTC, Dr. Jacobs led clinical programs from Phase
1 to Phase 4 across many therapeutic areas, including
ophthalmology, the central nervous system, and gastrointestinal
diseases, for several companies, including Biogen and Daiichi
Sankyo.
“We are excited to welcome Eduardo and David to AGTC as we
advance our lead clinical programs in X-linked retinitis pigmentosa
and achromatopsia, and expand our manufacturing capabilities,” said
Sue Washer, President, and CEO of AGTC. “With their deep and highly
relevant experience, we believe these leaders will be a key asset
to the Company as we advance our innovative gene therapies toward
potential commercialization and work to complete the buildout of
our new manufacturing facility in Alachua, Florida.”
About AGTC
AGTC is a clinical-stage biotechnology company developing
genetic therapies for people with rare and debilitating ophthalmic,
otologic and central nervous system (CNS) diseases. AGTC is a
leader in designing and constructing all critical gene therapy
elements and bringing them together to develop customized therapies
with the potential to address unmet patient needs. AGTC’s most
advanced clinical programs leverage its best-in-class technology
platform to potentially improve vision for patients with inherited
retinal diseases. AGTC has active clinical trials in X-linked
retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3). Its
preclinical programs build on the company’s industry leading AAV
manufacturing technology and scientific expertise. AGTC is
advancing multiple important pipeline candidates to address
substantial unmet clinical needs in optogenetics, otology and CNS
disorders, and has entered strategic collaborations with companies
including Bionic Sight, an innovator in the emerging field of
optogenetics, and retinal coding and Otonomy, Inc., a
biopharmaceutical company dedicated to the development of
innovative therapeutics for neurotology. For more information,
please visit https://agtc.com/.
Forward-Looking Statements This release
contains forward-looking statements that reflect AGTC's plans,
estimates, assumptions and beliefs, including statements about the
potential of the company’s gene therapy platform, its pipeline
including its development plans for its product candidates to treat
XLRP and ACHM CNGB3, and the completion and operation of its
planned manufacturing facility. Forward-looking statements include
all statements that are not historical facts and can be identified
by terms such as "anticipates," "believes," "could," "seeks,"
"estimates," "expects," "intends," "may," "plans," "potential,"
"predicts," "projects," "should," "will," "would" or similar
expressions and the negatives of those terms. Actual results could
differ materially from those discussed in the forward-looking
statements, due to a number of important factors. Risks
and uncertainties that may cause actual results to differ
materially include, among others: gene therapy is still novel with
only a few approved treatments so far; AGTC cannot predict when or
if it will obtain regulatory approval to commercialize its product
candidates for XLRP or ACHM CNGB3 or receive reasonable
reimbursement; risks and uncertainties associated with drug
development, regulatory review and commercialization; risks and
uncertainties related to funding sources for the Company’s
development programs; risks related to the completion and operation
of the Company’s planned manufacturing facility, the direct and
indirect impacts of the ongoing COVID-19 pandemic on the Company’s
business, results of operations, and financial condition; factors
that could cause actual results to differ materially from those
described in the forward-looking statements are set forth under the
heading "Risk Factors" in the company’s most recent annual report
on Form 10-K, as it may be supplemented by subsequent periodic
reports filed with the SEC. Given these uncertainties, you
should not place undue reliance on these forward-looking
statements. Also, forward-looking statements represent management's
plans, estimates, assumptions and beliefs only as of the date of
this release. Except as required by law, we assume no obligation to
update these forward-looking statements publicly or to update the
reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new
information becomes available in the
future.
PR Contact:
Kerry Sinclair
Spectrum Science Communications
ksinclair@spectrumscience.com
Corporate Contact:
Jonathan Lieber
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5778
jlieber@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024